Recovery of long-term natural protection against reactivation of CMV retinitis in AIDS patients responding to highly active antiretroviral therapy

J Infect. 1999 Nov;39(3):193-7. doi: 10.1016/s0163-4453(99)90048-8.

Abstract

Objectives: To see whether in severely immunosuppressed AIDS patients (with prior Cytomegalovirus retinal disease) who have significant increases in CD4+ lymphocytes following the initiation of highly active antiretroviral therapy (HAART) anti-Cytomegalovirus (CMV) maintenance therapy can be withdrawn with no subsequent progression of CMV retinitis.

Methods: Eight patients with AIDS and one or more previous episodes of CMV retinitis interrupted anti-CMV maintenance therapy following the successful beginning of HAART. CD4 cell counts and HIV-RNA were monitored monthly while measurement of CMV antigenemia and ophthalmoscopy were carried every 2 weeks thereafter.

Results: The HAART recipients in whom anti-CMV maintenance therapy had been interrupted had measureable increases of CD4+ T lymphocytes, substantial control of both HIV-RNA and CMV viraemia and did not show recurrence of retinitis during a mean follow-up of 98.4 weeks (range 78-120, SD 15.2).

Conclusions: Anti-CMV maintenance therapy can be interrupted with no subsequent progression of retinal damage over a long time in patients with AIDS who successfully respond to HAART with a significant increase in CD4 cell count.

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy*
  • Acquired Immunodeficiency Syndrome / drug therapy*
  • Acquired Immunodeficiency Syndrome / immunology
  • Adult
  • Anti-HIV Agents / therapeutic use*
  • Antigens, Viral / blood
  • Antiviral Agents / therapeutic use*
  • CD4 Lymphocyte Count
  • Cytomegalovirus Retinitis / drug therapy*
  • Female
  • Humans
  • Male
  • Middle Aged
  • RNA, Viral / blood

Substances

  • Anti-HIV Agents
  • Antigens, Viral
  • Antiviral Agents
  • RNA, Viral